Search

Search Constraints

You searched for: Date 2016 Author/Creator Rodriguez, M.

Search Results

2. CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors. (December 2016)